on December 28, 2006
Published online before print December 28, 2006, doi: 10.1161/01.ATV.0000256469.06782.d5
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on September 13, 2006
Accepted on December 7, 2006
Effects of Peroxisome Proliferator-Activated Receptor Ligands, Bezafibrate and Fenofibrate, on Adiponectin Level
Aki Hiuge ;
From Department of Metabolic Medicine (A.H., N.M., M.K., T.H., K.F., H.N., S.K., I.S., T.F.), Graduate School of Medicine, Osaka University, Osaka, Japan; Cardiac Rehabilitation Institute (A.T., E.Z.F., M.M.), The Israel Society for the Prevention of Hearth Attacks (ISPHA) (M.B., D.T., S.B.), the Bezafibrate Infarction Prevention Study Coordinating Center, Neufeld Cardiac Research Institute, the Chaim Sheba Medical Center, Tel-Hashomer; Biochemistry Laboratory (Z.M.), Wolfson Medical Center, Holon, Israel, affiliated with the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
* To whom correspondence should be addressed. E-mail: nmaeda{at}imed2.med.osaka-u.ac.jp.
Objective--Adiponectin is adipose-specific secretory protein and acts as anti-diabetic and anti-atherosclerotic molecule. We previously found peroxisome proliferators response element in adiponectin promoter region, suggesting that peroxisome proliferator-activated receptor (PPAR) ligands elevate adiponectin. Fibrates are known to be PPAR
ligands and were shown to reduce risks of diabetes and cardiovascular disease. Effect of fibrates on adiponectin has not been clarified, whereas thiazolidinediones enhance adiponectin. Thus, we explored the possibility and mechanism that fibrates enhance adiponectin in humans, mice, and cells.
Methods and Results--Significant increase of serum adiponectin was observed in bezafibrate-treated subjects compared with placebo group in patients enrolled in The Bezafibrate Infarction Prevention study. Higher baseline adiponectin levels were strongly associated with reduced risk of new diabetes. Fibrates, bezafibrate and fenofibrate, significantly elevated adiponectin levels in wild-type mice and 3T3-L1 adipocytes. Such an effect was not observed in PPAR-deficient mice and adipocytes. Fibrates activated adiponectin promoter but failed to enhance its activity when the point mutation occurred in peroxisome proliferators response element site and the endogenous PPAR was knocked down by PPAR-RNAi.
Conclusions--Our results suggest that fibrates enhance adiponectin partly through adipose PPAR and measurement of adiponectin might be a useful tool for searching subjects at high risk for diabetes.
Key words: adipocyte • adiponectin • fibrate • metabolic syndrome • peroxisome proliferator-activated receptor
This article has been cited by other articles:
 |
|
 |
|
  Y. Nakagawa, K. Kishida, S. Kihara, M. Sonoda, A. Hirata, A. Yasui, H. Nishizawa, T. Nakamura, R. Yoshida, I. Shimomura, et al. Nocturnal reduction in circulating adiponectin concentrations related to hypoxic stress in severe obstructive sleep apnea-hypopnea syndrome Am J Physiol Endocrinol Metab, April 1, 2008; 294(4): E778 - E784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. S. Packard and P. Libby Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction Clin. Chem., January 1, 2008; 54(1): 24 - 38. [Abstract] [Full Text] [PDF]
|
|